Screener
CRISPR Therapeutics CRSP Total Liabilities & Equity
Total Liabilities & Equity at other companies
Other financials
Where this comes from
Reported directly by CRISPR Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:LiabilitiesAndStockholdersEquity.
The source filing: CRISPR Therapeutics’s 10-Q, filed May 4, 2026.
- Filed
- May 4, 2026, 4:48 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001193125-26-204188
| Line item | As of / March 31, 2026 | As of / December 31, 2025 |
|---|---|---|
| Shareholders’ equity: | ||
| Common shares, CHF 0.03 nominal value, 132,477,166 shares authorized at March 31, 2026 and at December 31, 2025, 96,500,822 and 96,009,657 shares issued at March 31, 2026 and December 31, 2025, respectively, 96,385,506 and 95,894,341 shares outstanding at March 31, 2026 and December 31, 2025, respectively | 3,115 | 3,087 |
| Treasury shares, at cost, 115,316 shares at March 31, 2026 and at December 31, 2025 | (60) | (60) |
| Additional paid-in capital | 3,883,924 | 3,861,516 |
| Accumulated deficit | (2,070,482) | (1,947,551) |
| Accumulated other comprehensive (loss) income | (1,941) | 4,821 |
| Total shareholders’ equity | 1,814,556 | 1,921,813 |
| Total liabilities and shareholders’ equity | $2,725,820 | $2,265,243 |
Item 1. Financial Statements
FAQ
- What is CRISPR Therapeutics's total liabilities & equity?
- CRISPR Therapeutics (CRSP) reported total liabilities & equity of $2.73B in Q1 2026.
- How has CRISPR Therapeutics's total liabilities & equity changed year-over-year?
- CRISPR Therapeutics's total liabilities & equity increased by 25.8% year-over-year, from $2.17B to $2.73B.
- What is the long-term trend for CRISPR Therapeutics's total liabilities & equity?
- Over 5 years (2020 to 2025), CRISPR Therapeutics's total liabilities & equity has grown at a 4.4% compound annual growth rate (CAGR), from $1.83B to $2.27B.
- What does total liabilities & equity mean?
- Total assets = total liabilities + total equity. This must always balance — a fundamental accounting identity.
Ask your AI about CRISPR Therapeutics's total liabilities & equity.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude